TipRanks
Cardiff Oncology, Inc. (DE:XE7C)
FRANKFURT:XE7C
Germany Market
XE7C
Cardiff Oncology
RESEARCH TOOLSreports

Cardiff Oncology (XE7C) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

XE7C Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Cardiff
Oncology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XE7C Stock 12 Month Forecast

Average Price Target

€6.67
▲(896.16% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is €6.67 with a high forecast of €8.01 and a low forecast of €5.34. The average price target represents a 896.16% change from the last price of €0.67.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","9":"€9","-1":"-€1","1.5":"€1.5","6.5":"€6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.00913393,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.674278275000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.33942262,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.567779533076923,2.104559066153846,2.641338599230769,3.1781181323076924,3.7148976653846155,4.251677198461539,4.788456731538462,5.325236264615385,5.862015797692308,6.398795330769231,6.9355748638461545,7.472354396923078,{"y":8.00913393,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.4650983288461539,1.8991966576923076,2.3332949865384616,2.7673933153846155,3.201491644230769,3.6355899730769234,4.069688301923077,4.503786630769231,4.937884959615385,5.371983288461538,5.806081617307693,6.240179946153846,{"y":6.674278275000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.3624171246153844,1.6938342492307692,2.025251373846154,2.3566684984615387,2.6880856230769234,3.0195027476923078,3.350919872307692,3.682336996923077,4.013754121538462,4.345171246153846,4.676588370769231,5.008005495384616,{"y":5.33942262,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.664,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.862,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.425,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.362,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.552,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.322,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.301,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.312,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.056,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.662,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.776,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.031,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€8.01Average Price Target€6.67Lowest Price Target€5.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:XE7C
Robert Burns
H.C. Wainwright
H.C. Wainwright
€8.01
Buy
1095.39%
Upside
Upgraded
09/15/26
Cardiff Oncology upgraded to Buy from Neutral at H.C. WainwrightCardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright
Craig-Hallum Analyst forecast on DE:XE7C
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Hold
―
Reiterated
09/15/26
Analysts Conflicted on These Healthcare Names: High Tide (NASDAQ: HITI), Cardiff Oncology (NASDAQ: CRDF) and Benitec Biopharma (NASDAQ: BNTC)
William Blair Analyst forecast on DE:XE7C
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Addus Homecare (NASDAQ: ADUS) and Cardiff Oncology (NASDAQ: CRDF)
TD Cowen Analyst forecast on DE:XE7C
Marc Frahm
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE) and Cardiff Oncology (NASDAQ: CRDF)
Piper Sandler Analyst forecast on DE:XE7C
Edward Tenthoff
Piper Sandler
Piper Sandler
€5.34
Buy
696.93%
Upside
Reiterated
08/12/26
Piper Sandler Remains a Buy on Cardiff Oncology (CRDF)
Lucid Capital Analyst forecast on DE:XE7C
Christopher Liu
Lucid Capital
Lucid Capital
€8.9→€3.56
Buy
431.29%
Upside
Reiterated
06/05/26
Cardiff Oncology price target lowered to $4 from $10 at Lucid CapitalCardiff Oncology price target lowered to $4 from $10 at Lucid Capital
Noble Financial Analyst forecast on DE:XE7C
Robert LeBoyer
Noble Financial
Noble Financial
€10.68
Buy
1493.86%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
Ladenburg Thalmann & Co. Analyst forecast on DE:XE7C
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€16.91
Buy
2423.61%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:XE7C
Robert Burns
H.C. Wainwright
H.C. Wainwright
€8.01
Buy
1095.39%
Upside
Upgraded
09/15/26
Cardiff Oncology upgraded to Buy from Neutral at H.C. WainwrightCardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright
Craig-Hallum Analyst forecast on DE:XE7C
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Hold
―
Reiterated
09/15/26
Analysts Conflicted on These Healthcare Names: High Tide (NASDAQ: HITI), Cardiff Oncology (NASDAQ: CRDF) and Benitec Biopharma (NASDAQ: BNTC)
William Blair Analyst forecast on DE:XE7C
Andy Hsieh
William Blair
William Blair
―
Hold
―
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Addus Homecare (NASDAQ: ADUS) and Cardiff Oncology (NASDAQ: CRDF)
TD Cowen Analyst forecast on DE:XE7C
Marc Frahm
TD Cowen
TD Cowen
―
Hold
―
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE) and Cardiff Oncology (NASDAQ: CRDF)
Piper Sandler Analyst forecast on DE:XE7C
Edward Tenthoff
Piper Sandler
Piper Sandler
€5.34
Buy
696.93%
Upside
Reiterated
08/12/26
Piper Sandler Remains a Buy on Cardiff Oncology (CRDF)
Lucid Capital Analyst forecast on DE:XE7C
Christopher Liu
Lucid Capital
Lucid Capital
€8.9→€3.56
Buy
431.29%
Upside
Reiterated
06/05/26
Cardiff Oncology price target lowered to $4 from $10 at Lucid CapitalCardiff Oncology price target lowered to $4 from $10 at Lucid Capital
Noble Financial Analyst forecast on DE:XE7C
Robert LeBoyer
Noble Financial
Noble Financial
€10.68
Buy
1493.86%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
Ladenburg Thalmann & Co. Analyst forecast on DE:XE7C
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€16.91
Buy
2423.61%
Upside
Reiterated
11/10/25
Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
REPLReplimune Group
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cardiff Oncology

3 Months
Robert BurnsH.C. Wainwright
Success Rate
2/12 ratings generated profit
17%
Average Return
-12.53%
Copying Robert Burns's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -12.53% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
0/12 ratings generated profit
0%
Average Return
-28.41%
Copying Robert Burns's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -28.41% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
0/12 ratings generated profit
0%
Average Return
-29.81%
Copying Robert Burns's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -29.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XE7C Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
6
5
2
2
2
Buy
5
5
1
0
0
Hold
3
3
5
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
13
8
6
6
In the current month, XE7C has received 2 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. XE7C average Analyst price target in the past 3 months is 6.67.
Each month's total comprises the sum of three months' worth of ratings.

XE7C Financial Forecast

XE7C Earnings Forecast

Next quarter’s earnings estimate for XE7C is -€0.12 with a range of -€0.16 to -€0.10. The previous quarter’s EPS was -€0.12. XE7C beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE7C has Performed in-line its overall industry.
Next quarter’s earnings estimate for XE7C is -€0.12 with a range of -€0.16 to -€0.10. The previous quarter’s EPS was -€0.12. XE7C beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE7C has Performed in-line its overall industry.

XE7C Sales Forecast

Next quarter’s sales forecast for XE7C is €72.08K with a range of €0.00 to €133.49K. The previous quarter’s sales results were €92.55K. XE7C beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE7C has Performed in-line its overall industry.
Next quarter’s sales forecast for XE7C is €72.08K with a range of €0.00 to €133.49K. The previous quarter’s sales results were €92.55K. XE7C beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE7C has Performed in-line its overall industry.

XE7C Stock Forecast FAQ

What is DE:XE7C’s average 12-month price target, according to analysts?
Based on analyst ratings, Cardiff Oncology, Inc.’s 12-month average price target is 6.67.
    What is DE:XE7C’s upside potential, based on the analysts’ average price target?
    Cardiff Oncology, Inc. has 896.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Cardiff Oncology, Inc. a Buy, Sell or Hold?
          Cardiff Oncology, Inc. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Cardiff Oncology, Inc.’s share price target?
            The average share price target for Cardiff Oncology, Inc. is 6.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €8.01 ,and the lowest forecast is €5.34. The average share price target represents 896.16% Increase from the current price of €0.67.
              What do analysts say about Cardiff Oncology, Inc.?
              Cardiff Oncology, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Cardiff Oncology, Inc.?
                To buy shares of DE:XE7C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.